文献速递基础与转化研究新药、器械与细胞基因治疗研发

工程化CAR T细胞分泌VEGF中和scFv增强抗实体瘤活性

Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors.
PubMed 文献 · Sci Transl Med · 2026-03-04

实体瘤免疫抑制微环境限制CAR T细胞疗效,其中VEGF富集参与免疫抑制和血管异常。研究构建分泌抗VEGF单链可变片段(scFv)的CAR T细胞(CAR-αVEGF),在卵巢癌和胶质瘤多个体内模型中优于传统CAR T细胞及联合抗VEGF抗体治疗。机制上增强CAR T细胞活化与线粒体适应度,富集内源性免疫细胞免疫刺激特征,并规避抑制性髓系细胞浸润、血管异常和缺氧等靶向毒性。

要点

  • CAR-αVEGF T细胞在卵巢癌和胶质瘤体内模型中抗肿瘤疗效优于传统CAR T细胞。
  • 疗效优于传统CAR T细胞联合抗VEGF抗体治疗。
  • CAR-αVEGF T细胞增强自身活化与线粒体适应度,并改善肿瘤免疫微环境。

核心结论

  • 分泌抗VEGF scFv的CAR T细胞在多种实体瘤体内模型中显示增强的抗肿瘤活性,支持其临床转化用于VEGF升高的实体瘤。

研究设计与样本

  • 研究构建分泌抗VEGF单链可变片段的CAR T细胞(CAR-αVEGF T细胞)。
  • 在卵巢癌和胶质瘤多个体内模型中比较CAR-αVEGF T细胞与传统CAR T细胞及联合抗VEGF抗体治疗的疗效。

主要发现

  • CAR-αVEGF T细胞在多个卵巢癌和胶质瘤体内模型中抗肿瘤疗效优于传统CAR T细胞。
  • CAR-αVEGF T细胞疗效优于传统CAR T细胞联合抗VEGF抗体治疗。
  • 装甲抗VEGF scFv增强CAR T细胞活化和线粒体适应度,并在荷瘤脑内富集内源性免疫细胞的免疫刺激特征。
  • CAR-αVEGF T细胞规避靶向CAR T细胞治疗的多种不良效应,包括抑制性髓系细胞浸润、血管异常加重和缺氧。

临床怎么用

  • 对于VEGF升高的实体瘤,CAR-αVEGF T细胞策略可能提供优于传统CAR T细胞及联合抗VEGF抗体的治疗选择。
  • 该策略可能减轻靶向CAR T细胞治疗相关的抑制性髓系细胞浸润、血管异常和缺氧等不良效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy against solid tumors, which often reside in highly immunosuppressive tumor microenvironments (TMEs). TMEs can be highly abundant in vascular endothelial growth factor A (VEGF), which contributes to immunosuppression and abnormal tumor vasculature. Here, we found that CAR T cells engineered to secrete an anti-VEGF single-chain variable fragment (CAR-αVEGF T cells) achieved superior antitumor efficacy against multiple in vivo models of ovarian cancer and glioma, outperforming conventional CAR T cells with and without combination anti-VEGF antibody therapy. Microscopy, flow cytometry, and transcriptomic analyses revealed that armoring the CAR T cells with anti-VEGF single-chain variable fragments enhanced their activation and mitochondrial fitness and enriched immune-stimulatory signatures among endogenous immune cells in the tumor-bearing brain. Moreover, CAR-αVEGF T cells circumvented multiple detrimental effects associated with on-target CAR T cell therapy, including infiltration of suppressive myeloid cells, exaggerated vasculature abnormalities, and hypoxia. Together, our results provide rationale for the clinical translation of CAR-αVEGF T cells as a safe and potent therapy for solid tumors characterized by elevated VEGF.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Gao TA, Shih RM, Clubb JD, et al. Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors. Sci Transl Med. 2026. PMID: 41779870. doi:10.1126/scitranslmed.adw9286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。